H.C. Wainwright Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $90
Buy Rating Affirmed for Cytokinetics Following Promising Aficamten Clinical Trial Results
Cytokinetics Analyst Ratings
Jefferies Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $92
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $60 to $92
Truist Financial Issues a Buy Rating on Cytokinetics (CYTK)
Cytokinetics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $90 Price Target
Buy Rating Affirmed for Cytokinetics: Aficamten's Promising Future in HCM Treatment
B.Riley Financial Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $92
Buy Rating Justified for Cytokinetics Amid Promising Clinical Data and Drug Class Expansion Potential
Jefferies Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $92
Cytokinetics Analyst Ratings
Goldman Sachs Maintains Cytokinetics(CYTK.US) With Hold Rating, Maintains Target Price $60
Cautious Hold on Cytokinetics Amid Phase 2 Progress and Safety Concerns
BofA Securities Maintains Cytokinetics(CYTK.US) With Hold Rating, Maintains Target Price $60
H.C. Wainwright Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $90
Buy Rating Affirmed for Cytokinetics Amid Promising Cardiac Treatment Developments
HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $90 Price Target
Cytokinetics Is Maintained at Overweight by JP Morgan